argenx (ARGX) Scheduled to Post Earnings on Thursday

argenx (NASDAQ:ARGX) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect argenx to post earnings of ($0.71) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The firm had revenue of $417.84 million during the quarter, compared to analysts’ expectations of $378.60 million. During the same period in the previous year, the firm posted ($0.70) EPS. On average, analysts expect argenx to post $-2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

argenx Stock Up 1.3 %

NASDAQ:ARGX opened at $398.81 on Wednesday. The stock has a market capitalization of $23.70 billion, a PE ratio of -77.59 and a beta of 0.67. argenx has a 52 week low of $327.73 and a 52 week high of $550.76. The stock’s 50-day moving average price is $383.20 and its 200-day moving average price is $410.68.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ARGX shares. Truist Financial upped their target price on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Robert W. Baird reduced their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Piper Sandler lifted their price target on argenx from $518.00 to $522.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Wells Fargo & Company raised their price objective on argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a report on Tuesday, February 20th. Finally, Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $528.16.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.